ABT

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,686

SEC source: 0001415889-23-012074 · form4-08102023_100835.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-011571 · form4-07282023_090718.xml · nonDerivative · entry 2

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,775,316

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.86 to $114.46, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-23-011571 · form4-07282023_090718.xml · nonDerivative · entry 1

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,804,382

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.86 to $113.85, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001104659-23-077919 · tm2320556-2_4seq1.xml · nonDerivative · entry 2

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,915

SEC source: 0001104659-23-077918 · tm2320556-1_4seq1.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,266

Underlying: Common Shares · 72 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001104659-23-077919 · tm2320556-2_4seq1.xml · derivative · entry 4

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,100

Underlying: Common Shares · 7,100 shares

Expires 2033-06-29

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,366 on June 30, 2024, 2,367 on June 30, 2025, and 2,367 on June 30, 2026.

SEC source: 0001104659-23-077919 · tm2320556-2_4seq1.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,471

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001104659-23-077920 · tm2320556-3_4seq1.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,206

Underlying: Common Shares · 302 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001104659-23-077924 · tm2320556-4_4seq1.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,612

Underlying: Common Shares · 316 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001104659-23-077925 · tm2320556-5_4seq1.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,304

Underlying: Common Shares · 325 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-010065 · form4-06202023_100642.xml · nonDerivative · entry 1

Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,447

F1 · shares: The sale transaction was made pursuant to a Rule 10b5-1(c) plan adopted on February 24, 2023.

SEC source: 0001415889-23-007139 · form4-05032023_120522.xml · nonDerivative · entry 3

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,825,316

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-23-007139 · form4-05032023_120522.xml · nonDerivative · entry 2

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,828,768

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-23-007254 · form4-05032023_110540.xml · derivative · entry 3

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,226 shares

Expires 2025-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-007254 · form4-05032023_110540.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,427

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.5501 to $110.562, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-23-007254 · form4-05032023_110540.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,653

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-007126 · form4-05022023_110558.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,297

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007127 · form4-05022023_110537.xml · nonDerivative · entry 1

Babineaux-Fontenot Claire · CIK 0001736637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,816

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007128 · form4-05022023_110553.xml · nonDerivative · entry 1

Blount Sally E. · CIK 0001537286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,157

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007129 · form4-05022023_110519.xml · nonDerivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,418

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007130 · form4-05022023_110537.xml · nonDerivative · entry 1

Kumbier Michelle · CIK 0001640036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,213

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007133 · form4-05022023_110507.xml · nonDerivative · entry 1

McDew Darren W · CIK 0001787479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,891

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007136 · form4-05022023_110549.xml · derivative · entry 2

McKinstry Nancy · CIK 0001294731 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,861

Underlying: Common Shares · 9,861 shares

Expires 2033-04-27

F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-007136 · form4-05022023_110549.xml · nonDerivative · entry 1

McKinstry Nancy · CIK 0001294731 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,223

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007137 · form4-05022023_110522.xml · derivative · entry 2

O'Grady Michael · CIK 0001527742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,576

Underlying: Common Shares · 4,576 shares

Expires 2033-04-27

F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-007137 · form4-05022023_110522.xml · nonDerivative · entry 1

O'Grady Michael · CIK 0001527742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,816

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007138 · form4-05032023_120557.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,977

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2 · balance_after: Includes 60 shares that were acquired before Mr. Roman became an Abbott director and were not previously reported.

SEC source: 0001415889-23-007139 · form4-05032023_120522.xml · derivative · entry 5

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,136

Underlying: Common Shares · 8,136 shares

Expires 2033-04-27

F5 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-007139 · form4-05032023_120522.xml · nonDerivative · entry 1

STARKS DANIEL J · CIK 0000902132 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,875,316

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007143 · form4-05032023_120501.xml · nonDerivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,532

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-006148 · form4-04042023_110402.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,151

Underlying: Common Shares · 77 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-006150 · form4-04042023_110420.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,894

Underlying: Common Shares · 325 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-006151 · form4-04042023_110437.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,285

Underlying: Common Shares · 325 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-006153 · form4-04042023_110449.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,937

Underlying: Common Shares · 325 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-003886 · form4-03032023_120331.xml · nonDerivative · entry 2

Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,420

SEC source: 0001415889-23-003889 · form4-03032023_120359.xml · nonDerivative · entry 2

ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,959

SEC source: 0001415889-23-003899 · form4-03032023_120339.xml · nonDerivative · entry 2

DALE MICHAEL D · CIK 0001172346 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,133

SEC source: 0001415889-23-003901 · form4-03032023_120327.xml · nonDerivative · entry 2

Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,437

SEC source: 0001415889-23-003907 · form4-03032023_120303.xml · nonDerivative · entry 2

Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,237

SEC source: 0001415889-23-003908 · form4-03032023_120322.xml · nonDerivative · entry 2

Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,380

SEC source: 0001415889-23-003910 · form4-03032023_120319.xml · nonDerivative · entry 2

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,323

SEC source: 0001415889-23-003912 · form4-03032023_120314.xml · nonDerivative · entry 2

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,224

SEC source: 0001415889-23-003916 · form4-03032023_120315.xml · nonDerivative · entry 2

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,861

SEC source: 0001415889-23-003918 · form4-03032023_120300.xml · nonDerivative · entry 2

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,162

SEC source: 0001415889-23-003921 · form4-03032023_120354.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,427

SEC source: 0001415889-23-003922 · form4-03032023_120354.xml · nonDerivative · entry 2

Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,366

SEC source: 0001415889-23-003926 · form4-03032023_010311.xml · nonDerivative · entry 2

WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,203

SEC source: 0001415889-23-003886 · form4-03032023_120331.xml · nonDerivative · entry 1

Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,737

SEC source: 0001415889-23-003889 · form4-03032023_120359.xml · nonDerivative · entry 1

ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,028